Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms
May 15th 2008Drug InformationADHD
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
